| First Author | Wixler V | Year | 2022 |
| Journal | Mol Ther | Volume | 30 |
| Issue | 2 | Pages | 745-762 |
| PubMed ID | 34450252 | Mgi Jnum | J:347744 |
| Mgi Id | MGI:7627285 | Doi | 10.1016/j.ymthe.2021.08.030 |
| Citation | Wixler V, et al. (2022) Small spleen peptides prevent development of psoriatic arthritis via restoration of peripheral tolerance. Mol Ther 30(2):745-762 |
| abstractText | The major challenge in the treatment of autoimmune diseases is the restoration of the impaired peripheral immune tolerance that always accompanies the development of such diseases. Here, we show that small splenic peptides (SSPs) of whole spleen extract efficiently suppress the development of psoriatic arthritis in vivo, even in the presence of sustained levels of pro-inflammatory cytokines. SSPs target dendritic cells (DCs) and convert them into tolerogenic cells, which in turn differentiate naive CD4(+) cells into Foxp3-expressing T regulatory cells (Tregs). The latter requires direct contact between SSP-activated DCs and naive CD4(+) T cells via PD-1 and CTLA4 immune checkpoint receptors of T cells. Finally, depletion of Foxp3(+) Tregs in vivo abrogated the protective effect of SSPs on psoriatic arthritis development. We hypothesize that SSPs represent an intrinsic component of the adaptive immune system responsible for the physiological maintenance of peripheral tolerance and that therapeutically administered SSPs are able to restore imbalanced peripheral tolerance in autoimmune diseases. |
